We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2019 to May 2024
18:06 ET - Johnson & Johnson (JNJ) vows to fight in the courts and in negotiations with health insurers after Pfizer (PFE) announces it will begin selling a biosimilar version of Remicade, but JPMorgan still predicts JNJ will lose $1B in sales next year, about 20 cents a share. Remicade is one of JNJ's top-selling products. PFE will start selling its Inflectra biosimilar in late November. In a statement, JNJ threatens to defend its intellectual-property rights and compete in contract talks with payers. JPMorgan says JNJ should offset the lost sales due to growing sales from newer drugs like Darzalex, Imbruvica and Stelara. (jonathan.rockoff@wsj.com, @jonathanrockoff)
(END) Dow Jones Newswires
October 17, 2016 18:21 ET (22:21 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
